LEADER 05169nam 22006134a 450 001 9910830421403321 005 20230721004058.0 010 $a1-282-34230-4 010 $a9786612342301 010 $a0-470-69765-2 010 $a0-470-69807-1 035 $a(CKB)1000000000687194 035 $a(EBL)470126 035 $a(OCoLC)609848680 035 $a(SSID)ssj0000311858 035 $a(PQKBManifestationID)11205898 035 $a(PQKBTitleCode)TC0000311858 035 $a(PQKBWorkID)10329380 035 $a(PQKB)11616922 035 $a(MiAaPQ)EBC470126 035 $a(EXLCZ)991000000000687194 100 $a20070808d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTrans fatty acids$b[electronic resource] /$fedited by Albert J. Dijkstra, Richard J. Hamilton, Wolf Hamm 210 $aOxford ;$aAmes, Iowa $cBlackwell Pub.$d2008 215 $a1 online resource (258 p.) 300 $aDescription based upon print version of record. 311 $a1-4051-5691-0 320 $aIncludes bibliographical references and index. 327 $aTrans Fatty Acids; 2.5.2 Diabetes; Contents; Contributors; Preface; 1 Fatty acids:structure,occurrence,nomenclature,biosynthesis and properties; 1.1 Introduction; 1.2 Fatty acid nomenclature; 1.2.1 Saturated acids; 1.2.2 Monounsaturated acids; 1.2.3 Diunsaturated acids; 1.2.4 Triunsaturated acids; 1.3 Occurrence; 1.4 Fatty acid biosynthesis; 1.4.1 Saturated fatty acids; 1.4.2 Monoenoic fatty acids; 1.4.3 Polyunsaturated fatty acids; 1.5 Properties of trans fatty acids; 1.5.1 Melting points; 1.5.2 Ultraviolet spectra; 1.5.3 Infrared spectra; 1.5.4 Nuclear magnetic resonance spectroscopy 327 $a1.6 Labelling and legislation2 Trans fatty acids intake:epidemiology and health implications; 2.1 Introduction; 2.2 Food sources of trans fatty acids; 2.3 Trans fatty acids intake; 2.4 Trans fatty acids in human milk; 2.5 Trans fatty acids intake and health implications; 2.5.1 Coronary heart disease; 2.5.3 Cancer; 2.6 Concluding remarks; 3 Conjugated linoleic acid effects on body composition and clinical biomarkers of disease in animals and man:metabolic and cell mechanisms; 3.1 General introduction:conjugated linoleic acids and health 327 $a3.2 Structure,dietary origins and consumption of CLAs in man3.2.1 Structure; 3.2.2 Origins of CLAs in the human diet; 3.2.3 Dietary consumption of CLAs in man; 3.3 CLAs in cancer prevention and treatment; 3.3.1 Epidemiology of dietary fats and cancer risk; 3.3.2 CLAs and breast cancer; 3.3.3 CLAs and prostate cancer; 3.3.4 CLAs in gastrointestinal cancer; 3.3.5 CLAs and other cancers (hepatic, pancreatic and dermal); 3.4 Cellular mechanisms of CLAs' anti-cancer effects; 3.4.1 Inhibition of angiogenesis; 3.4.2 Attenuation of cancer metastasis; 3.4.3 Reduction of cancer cachexia 327 $a3.5 Effect of CLAs on body composition and energy metabolism in animals and men3.5.1 Body composition in animals; 3.5.2 Body composition in man; 3.5.3 Possible mechanisms underlying reported changes in body composition; 3.5.4 Efficacy of different CLA isomers in regulating body composition; 3.6 Other reported health benefits of CLAs; 3.6.1 Effects on insulin resistance and diabetes; 3.6.2 Modulation of immune functions; 3.6.3 Effects of CLAs on biomarkers of cardiovascular disease; 3.7 Reported adverse health effects of CLAs in vivo and in vitro; 3.8 Conclusions 327 $a4 Analysis of trans mono-and polyunsaturated fatty acids4.1 Introduction; 4.2 Isomeric fatty acids in the human diet; 4.3 Gas chromatography and Fourier transform infrared spectroscopy; 4.4 Direct GC analysis; 4.4.1 Analysis of monounsaturated isomers; 4.4.2 Isomers of linoleic and a-linolenic acids; 4.4.3 Resolution of eicosenoic and a-linolenic acid isomers; 4.4.4 Effect of the type of carrier gas and flow rate on cis and trans isomer resolution and fatty acid quantification; 4.4.5 Conjugated fatty acids 327 $a4.5 Silver nitrate thin-layer and high-performance liquid chromatography separation of cis and trans isomers 330 $aTrans fatty acids (TFAs) have been used for many years to impart desirable physical characteristics to fats and fat blends used in food manufacturing. However, clinical trials and epidemiological studies conducted over the last thirty years have shown that TFAs can increase "bad" cholesterol levels in the blood while reducing "good" cholesterol. Accordingly, they are also linked with increased risks of coronary heart disease, thrombosis and strokes. For this reason, the food industry has been obliged to find alternatives to TFAs, thus enabling it to meet the presumed consumer demand for 606 $aTrans fatty acids 615 0$aTrans fatty acids. 676 $a612.3/97 676 $a664.3 701 $aDijkstra$b Albert J$0845534 701 $aHamilton$b R. J$g(Richard John)$0902282 701 $aHamm$b Wolf$0902283 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830421403321 996 $aTrans fatty acids$92016859 997 $aUNINA